How FENIB Affects the Brain: Biology and Diagnosis

The symptoms of Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB) are the result of a “molecular traffic jam” inside the brain’s neurons. Understanding how this happens biologically can help clarify why the disease progresses and how doctors work to distinguish it from other conditions that look similar.

The Biology of Neuroserpin Buildup

In a healthy brain, the neuroserpin protein is produced and then secreted (released) from neurons to help regulate activity between brain cells ^[1]. In FENIB, a mutation in the SERPINI1 gene changes the shape of this protein, making it “sticky” ^[2].

Laboratory-supported models propose two main problems in the brain:

1. Misfolding and Polymerization: The mutant proteins do not fold into their correct shape. Instead, they link together into long chains called polymers ^[2].
2. Toxic Buildup in the ER: These protein chains are too large and misshapen to be released from the cell. They get stuck inside a part of the neuron called the endoplasmic reticulum (ER), which acts like the cell’s manufacturing and packaging center ^[1].

Over time, these trapped proteins form large clumps called inclusion bodies (historically known as Collins bodies) ^[3]. This buildup is associated with oxidative stress and damaging the cell’s energy-producing mitochondria ^[4]. As these neurons become damaged and eventually die, the brain begins to shrink (atrophy) and lose function ^[3].

Loss of Protection

While the toxic buildup of protein is a proposed major driver of the disease, researchers also believe there is a “loss of function” component ^[2]. Because the neuroserpin protein is stuck inside the cell, it cannot be released to perform its normal job—inhibiting certain enzymes that can damage brain tissue if left unchecked ^[5]. This double-hit of toxic buildup and loss of protection is a proposed mechanism for what makes FENIB so damaging to the nervous system.

Diagnostic Tools: MRI and Genetic Testing

Because FENIB is so rare, doctors use a combination of tools to reach a diagnosis:

• Genetic Testing: A pathogenic or likely pathogenic SERPINI1 variant in an appropriate clinical context supports a molecular diagnosis ^[6]. Identifying the exact mutation can sometimes provide a rough idea of how the disease might progress, as some mutations cause the protein to clump much faster than others ^[2]. A negative test or variant of uncertain significance does not confirm the disease and requires genetic counseling.
• Brain MRI: In many cases, an MRI will show atrophy (thinning or shrinkage) of the cerebrum (the large part of the brain responsible for thinking) or the cerebellum (the part responsible for balance and coordination) ^[3]. In early stages, some patients show very specific shrinkage in the prefrontal cortex, an area involved in attention and personality ^[7]. However, MRI findings are supportive and nonspecific, not diagnostic, and may be absent.
• Pathology: If a brain autopsy is performed, a pathologist can see the characteristic inclusion bodies using specific stains. These clumps are characteristic in the appropriate neuropathological setting ^[8]. Brain biopsy is invasive and is not a routine diagnostic step for living patients.

Distinguishing FENIB from “Mimics”

FENIB belongs to a group of disorders called Progressive Myoclonic Epilepsies (PME). These conditions all cause seizures, muscle jerks, and cognitive decline, making them easy to confuse.

Genetic testing is the primary way doctors tell these apart. While the symptoms look nearly identical, the underlying “broken” gene is different for each, which is why a precise genetic diagnosis is so critical for families ^[15].